Neuroblastoma Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Aum Bio, NanoPharma, Athenex, Actuate Therapeutics
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Neuroblastoma pipeline constitutes 35+ key companies continuously working towards developing 35+ Neuroblastoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.The Neuroblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Neuroblastoma Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuroblastoma Market.
Some of the key takeaways from the Neuroblastoma Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Neuroblastoma treatment therapies with a considerable amount of success over the years.
*
Neuroblastoma companies working in the treatment market are Aum Bio, NanoPharmaceuticals, Athenex, Inc., Actuate Therapeutics Inc., PersonGen BioTherapeutics, KC Pharmaceuticals, Jubilant Pharmova Limited, and others, are developing therapies for the Neuroblastoma treatment
*
Emerging Neuroblastoma therapies in the different phases of clinical trials are- AUM302, BG-P-TAT, KUR-501, 9-ING-41, TAA06, DFMO (Eflornithine HCl), Iobenguane (131I), and others are expected to have a significant impact on the Neuroblastoma market in the coming years.
*
In February 2024, Iwilfin, designed to address high-risk neuroblastoma, has gained FDA approval as the inaugural oral maintenance therapy for this condition in the United States.
*
DFMO hydrochloride hydrate, also known as eflornithine hydrochloride hydrate, is an enzyme decarboxylase inhibitor that is selective and irreversible. It inhibits ornithine decarboxylase, which is how it functions. It is presently being studied in Phase II for neuroblastoma.
Neuroblastoma Overview
A uncommon kind of cancer called neuroblastoma primarily affects infants and young children. It is formed by specialized nerve cells called neutrophils that are left over from an embryo's development in the womb. Most frequently, neuroblastoma affects one of the adrenal glands above the kidneys or the nerve tissue in the neck, chest, abdomen, or pelvis that runs parallel to the spinal cord. It has the potential to spread to other organs, including the skin, lymph nodes, liver, and bone marrow.
Get a Free Sample PDF Report to know more about Neuroblastoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/neuroblastoma-pipeline-insight [https://www.delveinsight.com/report-store/neuroblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Neuroblastoma Drugs Under Different Phases of Clinical Development Include:
*
PLK4 Inhibitor Program: ORIC Pharmaceuticals, Inc.
*
AUM302: Aum Bio
*
BG-P-TAT: NanoPharmaceuticals
*
KUR-501: Athenex, Inc.
*
9-ING-41: Actuate Therapeutics Inc.
*
TAA06: PersonGen BioTherapeutics
*
DFMO (Eflornithine HCl): KC Pharmaceuticals
*
Iobenguane (131I): Jubilant Pharmova Limited
Neuroblastoma Route of Administration
Neuroblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intra-articular
*
Intraocular
*
Intrathecal
*
Intravenous
*
Ophthalmic
*
Oral
*
Parenteral
*
Subcutaneous
*
Topical
*
Transdermal
Neuroblastoma Molecule Type
Neuroblastoma Products have been categorized under various Molecule types, such as
*
Oligonucleotide
*
Peptide
*
Small molecule
Neuroblastoma Pipeline Therapeutics Assessment
*
Neuroblastoma Assessment by Product Type
*
Neuroblastoma By Stage and Product Type
*
Neuroblastoma Assessment by Route of Administration
*
Neuroblastoma By Stage and Route of Administration
*
Neuroblastoma Assessment by Molecule Type
*
Neuroblastoma by Stage and Molecule Type
DelveInsight's Neuroblastoma Report covers around 35+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Neuroblastoma product details are provided in the report. Download the Neuroblastoma pipeline report to learn more about the emerging Neuroblastoma therapies [https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Neuroblastoma Therapeutics Market include:
Key companies developing therapies for Neuroblastoma are - Pfizer, Inc., Bayer AG, MacroGenics, Inc., Sartorius AG, CELLECTAR BIOSCIENCES, INC., PROVECTUS BIOPHARMACEUTICALS, INC., United Therapeutics Corporation, APEIRON Biologics AG, Baxter International, Y-mAbs Therapeutics, Inc., Amgen, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and others.
Neuroblastoma Pipeline Analysis:
The Neuroblastoma pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Neuroblastoma with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroblastoma Treatment.
*
Neuroblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Neuroblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroblastoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Neuroblastoma drugs and therapies [https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Neuroblastoma Pipeline Market Drivers
*
Increased Incidence of Neuroblastoma worldwide, innovations and the new product combinations are some of the important factors that are fueling the Neuroblastoma Market.
Neuroblastoma Pipeline Market Barriers
*
However, lack of Awareness, drug-related side effects and other factors are creating obstacles in the Neuroblastoma Market growth.
Scope of Neuroblastoma Pipeline Drug Insight
*
Coverage: Global
*
Key Neuroblastoma Companies: Aum Bio, NanoPharmaceuticals, Athenex, Inc., Actuate Therapeutics Inc., PersonGen BioTherapeutics, KC Pharmaceuticals, Jubilant Pharmova Limited, and others
*
Key Neuroblastoma Therapies: AUM302, BG-P-TAT, KUR-501, 9-ING-41, TAA06, DFMO (Eflornithine HCl), Iobenguane (131I), and others
*
Neuroblastoma Therapeutic Assessment: Neuroblastoma current marketed and Neuroblastoma emerging therapies
*
Neuroblastoma Market Dynamics: Neuroblastoma market drivers and Neuroblastoma market barriers
Request for Sample PDF Report for Neuroblastoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Neuroblastoma Report Introduction
2. Neuroblastoma Executive Summary
3. Neuroblastoma Overview
4. Neuroblastoma- Analytical Perspective In-depth Commercial Assessment
5. Neuroblastoma Pipeline Therapeutics
6. Neuroblastoma Late Stage Products (Phase II/III)
7. Neuroblastoma Mid Stage Products (Phase II)
8. Neuroblastoma Early Stage Products (Phase I)
9. Neuroblastoma Preclinical Stage Products
10. Neuroblastoma Therapeutics Assessment
11. Neuroblastoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Neuroblastoma Key Companies
14. Neuroblastoma Key Products
15. Neuroblastoma Unmet Needs
16 . Neuroblastoma Market Drivers and Barriers
17. Neuroblastoma Future Perspectives and Conclusion
18. Neuroblastoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuroblastoma-pipeline-drugs-analysis-report-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-aum-bio-nanopharma-athenex-actuate-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuroblastoma Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Aum Bio, NanoPharma, Athenex, Actuate Therapeutics here
News-ID: 3489295 • Views: …
More Releases from ABNewswire
Bromine MarketSize, Opportunities, Share, Top Manufacturers Analysis, Growth, Re …
The bromine market is expanding as demand rises in diverse industries such as pharmaceuticals, flame retardants, and oil and gas drilling fluids. Its versatility and unique properties make it indispensable in various applications, driving steady market growth.
The bromine market [https://www.marketsandmarkets.com/Market-Reports/bromine-market-42782196.html] is projected to grow from USD 3.6 billion in 2023 to USD 4.4 billion by 2028, at a CAGR of 4.2% from 2023 to 2028. The growth of the market…
Texas Choice Roofers Leads the Austin Roofer Industry With Exceptional Service A …
Texas Choice Roofers in Austin, known for its stellar reputation and unmatched expertise, leads the roofer industry with exceptional service. Its skilled team showcases expert craftsmanship and commitment to customer satisfaction. Setting new standards for roofing excellence prioritizes service quality and professionalism. Discover how Texas Choice Roofers continues to exceed expectations with innovative techniques and a focus on building strong customer relationships.
Texas Choice Roofers' Stellar Reputation
Texas Choice Roofers has earned…
Storm Code Roofing Emerges as Premier Roofing Provider In Plantation With Unmatc …
Storm Code Roofing has established itself as the leading roofing provider in Plantation, demonstrating unparalleled quality. They excel in their meticulous attention to detail, timely project completion, and dedication to using premium roofing materials for superior craftsmanship.
Storm Code Roofing has cemented its position as the top roofing [http://money.mymotherlode.com/clarkebroadcasting.mymotherlode/article/abnewswire-2024-3-7-peak-performance-storm-code-introduces-roofing-solutions/] provider in Plantation, showcasing unmatched quality. They excel in meticulous attention to detail, timely project completion, and commitment to using premium roofing…
Metla House Cleaning: San Diego's Trusted House Cleaning Company For Impeccable …
Metla House Cleaning in San Diego has built a reputation for outstanding home care. They provide top-notch service, use environmentally friendly products, and respond promptly.
Metla House Cleaning in San Diego earns trust for home care excellence. They offer exceptional service, eco-friendly products, and quick responses. Trust their dedicated team for tailored solutions at affordable rates. The team's expertise includes stain removal, odor elimination, and organization tips. Metla handles high-quality, deep…
More Releases for Neuroblastoma
Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market.
Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under…
Neuroblastoma - Pipeline Insight and Review, H1 2018
Market Research HUB has added a new report titled "Neuroblastoma - Pipeline Review, H1 2018, which provides an overview of the Neuroblastoma (Oncology) pipeline landscape. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include…
Neuroblastoma Treatment Pipeline Review H2 2017
Pune, India, 27th November 2017: WiseGuyReports announced addition of new report, titled “Neuroblastoma - Pipeline Review, H2 2017”.
Summary
Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen…
Neuroblastoma - Pipeline Insight and Therapeutic Assessment Reviewed in 2017
A fresh report has been added to the wide database of Market Research Hub (MRH). The research study is titled “Neuroblastoma - Pipeline Review, H2 2017”which encloses important data about the production, consumption, revenue and market share, merged with information related to the market scope and product overview. The report anticipates that the sector for pharmaceutical industry would rise at a positive CAGR during the period 2017-2022.
Click here for Free…
Neuroblastoma Treatment Market to Register Substantial Expansion by 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…